Get the Stockscreener App
5.79
7.42%
0.40
After Hours:
5.78
-0.010
-0.17%
Abeona Therapeutics Inc stock is traded at $5.79, with a volume of 1.89M.
It is up +7.42% in the last 24 hours and up +17.68% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$5.39
Open:
$5.36
24h Volume:
1.89M
Relative Volume:
1.39
Market Cap:
$267.91M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.2442
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
+5.46%
1M Performance:
+17.68%
6M Performance:
-1.19%
1Y Performance:
+22.93%
1-Day Range:
$5.31
$5.9088
1-Week Range:
$5.25
$6.16
52-Week Range:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.79 | 267.91M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics: Q1 Earnings Snapshot - Midland Daily News
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gene Therapy | ABEO Stock News - GuruFocus
ABEONA THERAPEUTICS INC. SEC 10-Q Report - TradingView
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - Bluefield Daily Telegraph
Breakthrough: First-Ever Gene Therapy for Rare Skin Disease Launches as Abeona Secures $155M Deal - Stock Titan
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030 - GlobeNewswire Inc.
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First C - GuruFocus
Abeona Therapeutics® and Lurie Children's Open First Center for - GuruFocus
Abeona Therapeutics (ABEO) Initiates Gene Therapy Rollout for Sk - GuruFocus
Best Momentum Stocks to Buy for May 8th - The Globe and Mail
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene ... - Eagle-Tribune
UPDATE -- Abeona Therapeutics® and Lurie Children's Open - GlobeNewswire
Breakthrough Gene Therapy ZEVASKYN Launches: First Treatment Center Opens for Rare Skin Disease RDEB - Stock Titan
Abeona Therapeutics® and Lurie Children's Open First Center - GlobeNewswire
Abeona Therapeutics And Lurie Children's Open First Center For Zevaskyntm Gene Therapy - marketscreener.com
First-Ever Gene Therapy Treatment Center Opens for Devastating Skin Disease RDEBWhat Patients Need to Know - Stock Titan
Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives - TipRanks
Abeona secures cash runway with $155m priority review voucher sale - Yahoo
Abeona sells FDA voucher for $155 million, eyes profitability By Investing.com - Investing.com Canada
Cleveland company enters $155M agreement to sell FDA voucher - Crain's Cleveland Business
Abeona Therapeutics to Sell Zevaskyn Priority Review Voucher for $155 Million; Shares Rise - marketscreener.com
Abeona sells speedy drug review voucher for $155M - BioPharma Dive
Abeona sells FDA voucher for $155 million, eyes profitability - Investing.com Australia
Abeona Therapeutics (ABEO) Plans to Sell Priority Review Voucher for $155 Million | ABEO Stock News - GuruFocus
Abeona Therapeutics Sells Priority Review Voucher for $155M - TipRanks
Abeona Therapeutics® Enters into Agreement to Sell Priority Revi - GuruFocus
Abeona Therapeutics Enters Into Agreement To Sell Priority Review Voucher - marketscreener.com
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | ABEO Stock News - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
Abeona prices rare cell disorder gene therapy at $3.1m - Pharmaphorum
Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. - Olean Times Herald
Stifel lifts Abeona stock target to $21, maintains buy rating By Investing.com - Investing.com Canada
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):